SCHEMBL15977751

SCHEMBL15977751

c1ccc(-c2c3ccccc3c(-c3cc4ccccc4c4ccccc34)c3ccc(-c4ccc(-c5cccnc5)cc4)cc23)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 9/20 0.61
CYP11B2 P19099 8/20 0.49
CYP19A1 P11511 5/20 0.49
CYP17A1 P05093 1/20 0.49
GPR84 Q9NQS5 1/20 0.48
DHODH Q02127 1/20 0.45
CYP1A2 P05177 3/20 0.41
CYP3A4 P08684 3/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
HSD17B1 P14061 1/20 0.41
CYP2B6 P20813 1/20 0.41
CYP2C19 P33261 1/20 0.41
HSD17B2 P37059 1/20 0.41
ERN1 O75460 1/20 0.41
PIK3CA P42336 1/20 0.40
CYP2A6 P11509 2/20 0.40
LMNA P02545 1/20 0.39
RAF1 P04049 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15977927 0.96 CYP11B1 (0.66) CYP11B1CYP11B2CYP19A1CYP17A1GPR84
SCHEMBL15977586 0.91 CYP11B1 (0.53) CYP11B1CYP11B2CYP19A1CYP17A1GPR84
SCHEMBL15977584 0.91 CYP11B1 (0.53) CYP11B1CYP11B2CYP19A1CYP17A1GPR84
SCHEMBL15977740 0.89 CYP11B1 (0.54) CYP11B1CYP11B2CYP19A1CYP17A1GPR84
SCHEMBL15977826 0.89 CYP11B1 (0.54) CYP11B1CYP11B2CYP19A1CYP17A1GPR84
SCHEMBL15977839 0.88 CYP11B1 (0.47) CYP11B1GPR84DHODHHSD17B1HSD17B2
SCHEMBL10030052 0.88 CYP11B1 (0.53) CYP11B1CYP11B2CYP19A1CYP17A1DHODH
SCHEMBL10030022 0.88 CYP11B1 (0.53) CYP11B1CYP11B2CYP19A1CYP17A1DHODH
SCHEMBL15977675 0.88 CYP11B1 (0.53) CYP11B1CYP11B2CYP19A1CYP17A1DHODH
SCHEMBL15977643 0.88 CYP11B1 (0.53) CYP11B1CYP11B2CYP19A1CYP17A1DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220416178-A1 COMPOSITION, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC APPARATUS IDEMITSU KOSAN CO.,LTD. (JP) 2022-12-29 US disclosed
US-9559311-B2 Anthracene derivative, organic-electroluminescence-device material, organic electroluminescence device, and electronic equipment IDEMITSU KOSAN CO., LTD. (JP) 2017-01-31 US disclosed
US-9559311-B2 Anthracene derivative, organic-electroluminescence-device material, organic electroluminescence device, and electronic equipment IDEMITSU KOSAN CO., LTD. (JP) 2017-01-31 US disclosed
US-20140239273-A1 ANTHRACENE DERIVATIVE, ORGANIC-ELECTROLUMINESCENCE-DEVICE MATERIAL, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC EQUIPMENT IDEMITSU KOSAN CO., LTD. (JP) 2014-08-28 US disclosed
US-20140239273-A1 ANTHRACENE DERIVATIVE, ORGANIC-ELECTROLUMINESCENCE-DEVICE MATERIAL, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC EQUIPMENT IDEMITSU KOSAN CO., LTD. (JP) 2014-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220416178-A1 COMPOSITION, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC APPARATUS PIEZO1, TMEM109, SLC39A14 CYP11B1 1241/4885CYP11B2 1585/4885CYP19A1 936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.